← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
NIDCD Methotrexate and Corticosteroid Autoimmune Inner Ear Disease Study
Also known as: Methotrexate, Corticosteroids, Autoimmunity in Inner Ear Disease, NCT00000361
Government-led study
Sponsor / Institution
Government-led study
Program Type
Therapeutic
Modality
Steroid/Anti-inflammatory
Stage
Phase 3
Status
Discontinued
Target Gene
—
Route / Mode
Systemic immunosuppressive therapy
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
United States
Population
adult, sensorineural, autoimmune-inner-ear-disease
Trial IDs
1
Mechanism
Terminated Phase 3 NIDCD study involving corticosteroids and methotrexate in sensorineural hearing loss associated with autoimmune inner ear disease.
Indications
Notes
Collapsed generated corticosteroids and methotrexate rows into one terminated NIDCD autoimmune-inner-ear-disease study. These generic immunosuppressive components should not appear as separate current product programs.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT00000361
Key Events
Clinical Trials (1)
Data Checks
government-led-studyregistry-only-evidencehistorical-studymerged-generated-intervention-armsstudy-level-not-standalone-product
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2